← Back to Search


Photodynamic Therapy for Esophageal Cancer

Phase 1
Waitlist Available
Led By Hans Gerdes, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adequate organ function defined at baseline as: ANC ≥1,000/ L; Platelets ≥75,000/ L; Hb ≥8.5 g/dl; INR ≤1.5 (except for patients who are on full-dose warfarin); Calculated creatinine clearance ≥50 ml/min (using Cockcroft-Gault method); Total serum bilirubin ≤1.5 mg/dL, or </= 2.5 mg/dL for patients with a known history of Gilbert's syndrome; AST/ALT ≤5× upper limit of normal; Able to provide written informed consent
Previous esophageal dilation is permitted, provided the patient has developed recurrent dysphagia since that procedure
Screening 3 weeks
Treatment Varies
Follow Up 60 days
Awards & highlights

Study Summary

This trial is testing a new cancer treatment to see what the highest safe dose is.

Who is the study for?
This trial is for adults with esophageal cancer that's inoperable or has spread to other organs. They should have a performance status indicating they can still carry out daily activities and must not have had recent systemic therapy. Adequate organ function is required, and women of childbearing potential must test negative for pregnancy and use contraception.Check my eligibility
What is being tested?
The study tests the highest safe dose of WST-11 VTP, a new photodynamic therapy using laser light to treat swallowing difficulties caused by esophageal cancer obstruction.See study design
What are the potential side effects?
Potential side effects are not explicitly listed but may include typical reactions to photodynamic therapies such as tissue inflammation, discomfort at the treatment site, photosensitivity reactions, or changes in blood parameters due to organ response.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I've had esophageal dilation but my swallowing difficulties returned.
I haven't had any cancer treatments like chemotherapy or immunotherapy in the last week.
I am able to live at home and care for most of my personal needs.
I have had radiation or surgery on my esophagus due to cancer coming back or not fully going away.
I am 18 years old or older.
My esophageal cancer diagnosis has been confirmed and reviewed.
My disease cannot be cured and has spread or cannot be treated with surgery or more radiation.
I am on blood thinners, but my doctor thinks it's safe to stop them temporarily.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~60 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 60 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximum tolerated laser fluence rate

Trial Design

1Treatment groups
Experimental Treatment
Group I: Vascular-targeted photodynamic therapy (VTP) using WST11Experimental Treatment1 Intervention
Participants will receive intravenous administration of WST11 at a dose of 4 mg/kg, infused over 10 minutes, during an endoscopy procedure, followed by immediate laser light application.

Find a Location

Who is running the clinical trial?

Steba Biotech S.A.OTHER
16 Previous Clinical Trials
1,291 Total Patients Enrolled
Weizmann Institute of ScienceOTHER
56 Previous Clinical Trials
39,378 Total Patients Enrolled
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,933 Previous Clinical Trials
585,608 Total Patients Enrolled

Media Library

WST 11-mediated VTP therapy (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT03133650 — Phase 1
Esophageal Cancer Research Study Groups: Vascular-targeted photodynamic therapy (VTP) using WST11
Esophageal Cancer Clinical Trial 2023: WST 11-mediated VTP therapy Highlights & Side Effects. Trial Name: NCT03133650 — Phase 1
WST 11-mediated VTP therapy (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03133650 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the Food and Drug Administration sanctioned WST 11-mediated VTP therapy?

"A score of 1 was assigned to WST 11-mediated VTP therapy due to the limited efficacy and safety data available from Phase 1 trials."

Answered by AI

Is enrollment for this experiment still accessible to participants?

"As per the clinicaltrials.gov record, this particular medical experiment is not actively seeking out patients at present. The trial was first announced on April 26th 2017 and last modified on October 25th 2022. Despite that, 73 other trials are currently calling for participants to register today."

Answered by AI
~1 spots leftby Feb 2025